FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756546688> ?p ?o ?g. }

• W2756546688 endingPage "88826" @default.
• W2756546688 startingPage "88815" @default.
• W2756546688 abstract "// Yukie Yoshii 1 , Mitsuyoshi Yoshimoto 2 , Hiroki Matsumoto 3 , Takako Furukawa 1, 4 , Ming-Rong Zhang 1 , Masayuki Inubushi 5 , Atsushi B. Tsuji 1 , Yasuhisa Fujibayashi 1 , Tatsuya Higashi 1 and Tsuneo Saga 1, 6 1 National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan 2 Division of Functional Imaging, National Cancer Center Hospital East, Kashiwa, Japan 3 Research Centre, Nihon Medi-Physics Co., Ltd., Sodegaura, Japan 4 Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan 5 Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Japan 6 Department of Diagnostic Radiology, Kyoto University Hospital, Kyoto, Japan Correspondence to: Yukie Yoshii, email: yoshii.yukie@qst.go.jp Keywords: 64 Cu-ATSM, angiogenesis, bevacizumab, hypoxia, vascular decrease Received: July 19, 2017     Accepted: August 17, 2017     Published: September 28, 2017 ABSTRACT Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent clinically used for various cancers. However, repeated use of this agent leads to tumor-decreased vascularity and hypoxia with activation of an HIF-1 signaling pathway, which results in drug delivery deficiency and induction of malignant behaviors in tumors. Here, we developed a novel strategy to treat tumors with bevacizumab-induced vascular decrease and hypoxia using 64 Cu-diacetyl-bis ( N 4 -methylthiosemicarbazone) ( 64 Cu-ATSM), a potential theranostic agent, which possesses high tissue permeability and can target over-reduced conditions under hypoxia in tumors, with a human colon carcinoma HT-29 tumor-bearing mouse model. The long-term treatment with bevacizumab caused decreased blood vessel density and activation of an HIF-1 signaling pathway; increased uptake of 64 Cu-ATSM was also observed despite limited blood vessel density in HT-29 tumors. In vivo high-resolution SPECT/PET/CT imaging confirmed reduced vascularity and increased proportion of 64 Cu-ATSM uptake areas within the bevacizumab-treated tumors. 64 Cu-ATSM therapy was effective to inhibit tumor growth and prolong survival of the bevacizumab-treated tumor-bearing mice without major adverse effects. In conclusion, 64 Cu-ATSM therapy effectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular decrease and hypoxia. 64 Cu-ATSM therapy could represent a novel approach as an add-on to antiangiogenic therapy." @default.
• W2756546688 created "2017-10-06" @default.
• W2756546688 creator A5009564545 @default.
• W2756546688 creator A5018868612 @default.
• W2756546688 creator A5023174439 @default.
• W2756546688 creator A5038612225 @default.
• W2756546688 creator A5045773865 @default.
• W2756546688 creator A5067101373 @default.
• W2756546688 creator A5077156821 @default.
• W2756546688 creator A5078489553 @default.
• W2756546688 creator A5078877030 @default.
• W2756546688 creator A5090371551 @default.
• W2756546688 date "2017-09-28" @default.
• W2756546688 modified "2023-09-28" @default.
• W2756546688 title "64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts" @default.
• W2756546688 cites W1495360933 @default.
• W2756546688 cites W1777438515 @default.
• W2756546688 cites W1842167960 @default.
• W2756546688 cites W1848872330 @default.
• W2756546688 cites W1965254121 @default.
• W2756546688 cites W1968538537 @default.
• W2756546688 cites W1969581950 @default.
• W2756546688 cites W1982845574 @default.
• W2756546688 cites W1999570342 @default.
• W2756546688 cites W2011987037 @default.
• W2756546688 cites W2017322644 @default.
• W2756546688 cites W2019735253 @default.
• W2756546688 cites W2023448884 @default.
• W2756546688 cites W2024511476 @default.
• W2756546688 cites W2042884540 @default.
• W2756546688 cites W2044905529 @default.
• W2756546688 cites W2057140325 @default.
• W2756546688 cites W2057997223 @default.
• W2756546688 cites W2069678255 @default.
• W2756546688 cites W2071846689 @default.
• W2756546688 cites W2086050544 @default.
• W2756546688 cites W2092275219 @default.
• W2756546688 cites W2111176717 @default.
• W2756546688 cites W2118147340 @default.
• W2756546688 cites W2119921452 @default.
• W2756546688 cites W2126842988 @default.
• W2756546688 cites W2136787437 @default.
• W2756546688 cites W2138075845 @default.
• W2756546688 cites W2144004122 @default.
• W2756546688 cites W2144893998 @default.
• W2756546688 cites W2154306077 @default.
• W2756546688 cites W2158636665 @default.
• W2756546688 cites W2167623148 @default.
• W2756546688 cites W2271621094 @default.
• W2756546688 cites W2300413511 @default.
• W2756546688 cites W2331683571 @default.
• W2756546688 cites W2504622976 @default.
• W2756546688 cites W628038580 @default.
• W2756546688 doi "https://doi.org/10.18632/oncotarget.21323" @default.
• W2756546688 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5687648" @default.
• W2756546688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29179478" @default.
• W2756546688 hasPublicationYear "2017" @default.
• W2756546688 type Work @default.
• W2756546688 sameAs 2756546688 @default.
• W2756546688 citedByCount "9" @default.
• W2756546688 countsByYear W27565466882019 @default.
• W2756546688 countsByYear W27565466882020 @default.
• W2756546688 countsByYear W27565466882021 @default.
• W2756546688 countsByYear W27565466882022 @default.
• W2756546688 crossrefType "journal-article" @default.
• W2756546688 hasAuthorship W2756546688A5009564545 @default.
• W2756546688 hasAuthorship W2756546688A5018868612 @default.
• W2756546688 hasAuthorship W2756546688A5023174439 @default.
• W2756546688 hasAuthorship W2756546688A5038612225 @default.
• W2756546688 hasAuthorship W2756546688A5045773865 @default.
• W2756546688 hasAuthorship W2756546688A5067101373 @default.
• W2756546688 hasAuthorship W2756546688A5077156821 @default.
• W2756546688 hasAuthorship W2756546688A5078489553 @default.
• W2756546688 hasAuthorship W2756546688A5078877030 @default.
• W2756546688 hasAuthorship W2756546688A5090371551 @default.
• W2756546688 hasBestOaLocation W27565466881 @default.
• W2756546688 hasConcept C121608353 @default.
• W2756546688 hasConcept C126322002 @default.
• W2756546688 hasConcept C142724271 @default.
• W2756546688 hasConcept C143998085 @default.
• W2756546688 hasConcept C167734588 @default.
• W2756546688 hasConcept C178790620 @default.
• W2756546688 hasConcept C185592680 @default.
• W2756546688 hasConcept C2776107976 @default.
• W2756546688 hasConcept C2776694085 @default.
• W2756546688 hasConcept C2777025900 @default.
• W2756546688 hasConcept C2777802072 @default.
• W2756546688 hasConcept C2779081379 @default.
• W2756546688 hasConcept C2780394083 @default.
• W2756546688 hasConcept C502942594 @default.
• W2756546688 hasConcept C509974204 @default.
• W2756546688 hasConcept C526805850 @default.
• W2756546688 hasConcept C540031477 @default.
• W2756546688 hasConcept C71924100 @default.
• W2756546688 hasConcept C7836513 @default.
• W2756546688 hasConceptScore W2756546688C121608353 @default.
• W2756546688 hasConceptScore W2756546688C126322002 @default.
• W2756546688 hasConceptScore W2756546688C142724271 @default.

• next